Detection of IgE anti-parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection : relation to Th2 cytokines

The immune profile of a parvovirus B19-infected patient (male, 8 years old) was studied on day 0 (initial presentation) and on days 14 and 210 post symptom presentation (psp). Before infection, the patient was skin test positive to various allergens, including ragweed and tree and grass pollens, and...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 108(2003), 2 vom: 15. Aug., Seite 152-8
1. Verfasser: Bluth, Martin H (VerfasserIn)
Weitere Verfasser: Norowitz, Kevin B, Chice, Seto, Shah, Vipin N, Nowakowski, Maja, Josephson, Alan S, Durkin, Helen G, Smith-Norowitz, Tamar A
Format: Aufsatz
Sprache:English
Veröffentlicht: 2003
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Case Reports Comparative Study Journal Article Antibodies, Viral Biomarkers CD56 Antigen Immunoglobulin G Immunoglobulin M RNA, Messenger Receptors, IgE mehr... Receptors, IgG Interleukin-10 130068-27-8 Interleukin-4 207137-56-2 Immunoglobulin E 37341-29-0
LEADER 01000naa a22002652 4500
001 NLM126744769
003 DE-627
005 20231222212524.0
007 tu
008 231222s2003 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0423.xml 
035 |a (DE-627)NLM126744769 
035 |a (NLM)12921761 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Bluth, Martin H  |e verfasserin  |4 aut 
245 1 0 |a Detection of IgE anti-parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection  |b relation to Th2 cytokines 
264 1 |c 2003 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 01.10.2003 
500 |a Date Revised 07.11.2019 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a The immune profile of a parvovirus B19-infected patient (male, 8 years old) was studied on day 0 (initial presentation) and on days 14 and 210 post symptom presentation (psp). Before infection, the patient was skin test positive to various allergens, including ragweed and tree and grass pollens, and had a serum IgE level of 150 IU/mL. On day 0, the patient was diagnosed as parvovirus B19 infected, as judged by the presence of IgG anti-parvovirus Abs in serum (EIA) and presentation of "slap cheek" rash. The patient's serum IgE level increased from 150 IU/mL before infection to 256 IU/mL on day 0, was 233 IU/mL on day 14, and returned to preinfection levels on day 210. In contrast, there was little change in the levels of serum IgM, IgG, or IgA (nephelometry). IgE anti-parvovirus B19 protein (VP-N) was detected in serum (Western blot) on days 0, 14, and 210, despite the decrease in total IgE on day 210. Although there was no increase in total numbers of blood CD23+ B cells on day 0, by day 14 the numbers of these cells increased dramatically (93%), remaining high on day 210. In contrast, there were virtually no changes in total numbers of CD4+ and CD8+ T cells or CD16/56+ NK precursor cells on days 0-210. On day 0, when IgG and IgE anti-parvovirus were detected in serum, patient's peripheral blood mononuclear cells (PBMC) expressed mRNA for the Th2 cytokines IL-4 and IL-10, but not for the Th1 cytokines IFN-gamma or IL-2. However, by day 14 psp, PBMC expressed mRNA for the Th1 cytokines IFN-gamma and IL-2, as well as for IL-4 and IL-10. This is the first demonstration of the existence of IgE anti-parvovirus B19 Ab. The presence of IgE anti-parvovirus B19 Ab in serum on day 0 and its persistence in serum 7 months psp suggests that IgE anti-parvovirus may be useful in prognosis of parvovirus B19 infection. Our results reinforce the idea that IgE, in general, may play a major role in anti-viral immunity, perhaps in conjunction with CD23+ cells. The results further suggest that clearance of this infection is accompanied by a switch to Th1 cytokines 
650 4 |a Case Reports 
650 4 |a Comparative Study 
650 4 |a Journal Article 
650 7 |a Antibodies, Viral  |2 NLM 
650 7 |a Biomarkers  |2 NLM 
650 7 |a CD56 Antigen  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Immunoglobulin M  |2 NLM 
650 7 |a RNA, Messenger  |2 NLM 
650 7 |a Receptors, IgE  |2 NLM 
650 7 |a Receptors, IgG  |2 NLM 
650 7 |a Interleukin-10  |2 NLM 
650 7 |a 130068-27-8  |2 NLM 
650 7 |a Interleukin-4  |2 NLM 
650 7 |a 207137-56-2  |2 NLM 
650 7 |a Immunoglobulin E  |2 NLM 
650 7 |a 37341-29-0  |2 NLM 
700 1 |a Norowitz, Kevin B  |e verfasserin  |4 aut 
700 1 |a Chice, Seto  |e verfasserin  |4 aut 
700 1 |a Shah, Vipin N  |e verfasserin  |4 aut 
700 1 |a Nowakowski, Maja  |e verfasserin  |4 aut 
700 1 |a Josephson, Alan S  |e verfasserin  |4 aut 
700 1 |a Durkin, Helen G  |e verfasserin  |4 aut 
700 1 |a Smith-Norowitz, Tamar A  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 108(2003), 2 vom: 15. Aug., Seite 152-8  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:108  |g year:2003  |g number:2  |g day:15  |g month:08  |g pages:152-8 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 108  |j 2003  |e 2  |b 15  |c 08  |h 152-8